Biblio Discovery — Demo Discovery Service

9 results for "Adalgisa Condoluci"

Showing 1–9 · 0.21 seconds · RSS

  1. Journal Article

    Biology and Treatment of Richter Transformation

    Adalgisa Condoluci; Davide Rossi

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    Richter transformation (RT), defined as the development of an aggressive lymphoma on a background of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), represents a clinical unmet need because of its dismal prognosis. An increasing body of knowledge in the field of RT is arising…

  2. Journal Article

    How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic

    Davide Rossi; Mazyar Shadman; Adalgisa Condoluci et al.

    HemaSphere, Vol. 4 No. 4 · 2020 · English · DOAJ Scopus

    Abstract. Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and background risk factors that apply to the general…

  3. Journal Article

    The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment

    Vanessa Cristaldi; Lodovico Terzi di Bergamo; Lucrezia Patruno et al.

    Frontiers in Oncology, Vol. 15 · 2025 · English · DOAJ Scopus

    Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed/refractory (R/R) cHL patients treated with CBT achieve complete remission. In this study, we extensively…

  4. Journal Article

    Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

    Fortunato Morabito; Giovanni Tripepi; Riccardo Moia et al.

    Frontiers in Oncology, Vol. 11 · 2021 · English · DOAJ Scopus

    The prognostic role of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was recognized more than three decades ago when the neoplastic clone’s biology was almost unknown. LDT was defined as the time needed for the peripheral blood lymphocyte count to double the of the initial…

  5. Journal Article

    Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

    Rahel Schwotzer; Andreas J. Flammer; Sabine Gerull et al.

    Swiss Medical Weekly, Vol. 150 No. 4950 · 2020 · English · DOAJ Scopus

    Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function. There are more than 30 different proteins, known to be amyloidogenic with…

  6. Journal Article

    Management of transthyretin amyloidosis

    Adalgisa Condoluci; Marie Théaudin; Rahel Schwotzer et al.

    Swiss Medical Weekly, Vol. 151 No. 4142 · 2021 · English · DOAJ Scopus

    This article was corrected and republished online on November 4, 2021. Please see Erratum (Swiss Med Wkly. 2021;151:w30104)